Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) is a neuroscience company focused on developing and commercializing innovative treatments for rare neurological diseases. The company operates through wholly owned subsidiaries Harmony Biosciences, LLC and Harmony Biosciences Management, Inc. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Harmony Biosciences Holdings, Inc. does
In the company’s own words
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) is a neuroscience company focused on developing and commercializing innovative treatments for rare neurological diseases. The company operates through wholly owned subsidiaries Harmony Biosciences, LLC and Harmony Biosciences Management, Inc.
The company's commercial foundation rests on WAKIX (pitolisant), a first-in-class H3 receptor antagonist approved by the FDA for treating excessive daytime sleepiness and cataplexy in both adult and pediatric patients six years and older with narcolepsy. WAKIX generated net product revenue of $868.5 million for the year ended December 31, 2025, with approximately 8,500 patients on the medication as of the fourth quarter of 2025. The product represents a differentiated offering as the only FDA-approved non-scheduled treatment for narcolepsy, administered as a once-daily oral tablet.
Beyond its lead narcolepsy franchise, Harmony maintains a diversified pipeline spanning sleep and wake disorders, rare epilepsy, and neurobehavioral conditions. The company is advancing pitolisant in late-stage clinical programs for idiopathic hypersomnia, Prader-Willi syndrome, and myotonic dystrophy type 1. Next-generation pitolisant formulations, including pitolisant gastro-resistant and pitolisant high-dose, are in clinical development with potential applications across multiple indications. The company also sublicensed BP1.15205, an orexin 2 receptor agonist, from Bioprojet for development in the United States and Latin America.
Harmony's rare epilepsy franchise includes EPX-100 and EPX-200, acquired through the Zynerba Pharmaceuticals acquisition, with EPX-100 currently in Phase 3 registrational trials for Dravet syndrome and Lennox-Gastaut syndrome. The company also holds development rights to ZYN002, a transdermal cannabidiol gel for neurological conditions.
The company's intellectual property portfolio includes exclusive licensing agreements with Bioprojet Société Civile de Recherche for pitolisant-based products and related patent protections extending into the 2040s. Harmony operates through specialty pharmaceutical distributors and maintains manufacturing relationships with multiple contract development and manufacturing organizations to support its commercial and development operations.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- PLYMOUTH MEETING, PA
- Fiscal year end
- December
- CIK
- 1802665
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Harmony Biosciences Holdings, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Harmony Biosciences Holdings, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Harmony Biosciences Holdings, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Harmony Biosciences Holdings, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Harmony Biosciences Holdings, Inc.'s last four quarterly filings that the numbers alone won't show?”